AdipoGen Life Sciences

PD 98,059

CHF 25.00
In stock
AG-CR1-0118-M0011 mgCHF 25.00
AG-CR1-0118-M0055 mgCHF 80.00
AG-CR1-0118-M01010 mgCHF 120.00
AG-CR1-0118-M05050 mgCHF 360.00
More Information
Product Details
Synonyms PD 98059, 2'-Amino-3'-methoxyflavone
Product Type Chemical
Properties
Formula

C16H13NO3

MW 267.3
CAS 167869-21-8
Purity Chemicals ≥98% (NMR)
Appearance Yellow solid.
Solubility Soluble in anhydrous DMSO, methanol or dichloromethane. Slightly soluble in ethanol.
InChi Key QFWCYNPOPKQOKV-UHFFFAOYSA-N
Smiles COC1=C(N)C(=CC=C1)C1=CC(=O)C2=CC=CC=C2O1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Store solutions at -20°C in the dark.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • Highly selective, reversible and cell permeable MEK (MAP kinase kinase) inhibitor [1-3, 7]. 
  • Blocks the phosphorylation and activation of the MAP kinase pathway [1-3, 7]. 
  • T cell activation inhibitor [4].
  • Inhibits cell growth and cell proliferation of several cancer cells [5, 6, 8].
Product References
  1. A synthetic inhibitor of the mitogen-activated protein kinase cascade: D.T. Dudley, et al.; PNAS 92, 7686 (1995)
  2. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor: L. Pang, et al.; J. Biol. Chem. 270, 13585 (1995) 
  3. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo: D. Alessi, et al.; J. Biol. Chem. 270, 27489 (1995)
  4. Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production: F.J. Dumont, et al.; J. Immunol. 160, 2579 (1998)
  5. A phosphatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in human diploid fibroblasts: M. Tresini, et al.; Cancer Res. 58, 1 (1998)
  6. PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma: C. Simon, et al.; Br. J. Cancer 80, 1412 (1999)
  7. Specificity and mechanism of action of some commonly used protein kinase inhibitors. S.P. Davies, et al.; Biochem. J. 351, 95 (2000)
  8. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells:  K. Kojima, et al.; Cancer Res. 67, 3210 (2007)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.